Related Experiment Video
Updated: Aug 9, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Conclusions on the management of heart failure
1Department of Medicine, Sahlgrenska University Hospital, Gothernburg, Sweden. karl.swedberg@hjl.gu.se
Abstract:
Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure. Agents which act on the RAAS can be expected to benefit these patients. Recent trials which have furthered our understanding of drugs which are of benefit in heart failure--angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers and aldosterone antagonists--are discussed. It is desirable to use multiple agents for best results in patients with heart failure. New European Society of Cardiology guidelines on the management of heart failure are expected later this year.
More Related Videos
Related Concept Videos
Mitral Regurgitation IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions

